Research Paper Volume 16, Issue 2 pp 1640—1662

FABP6 serves as a new therapeutic target in esophageal tumor

class="figure-viewer-img"

Figure 7. Displays the experimental verification of our study. (A) showcases the expression of FABP6 in diverse esophageal cancer cell lines, providing evidence of FABP6’s promotion of migratory capability in ESCA cells. (BD) present the results obtained from qPCR and Western blotting analyses, which demonstrated the successful silencing of FABP6 expression in the ECA-109 and KYSE30 cell lines using siRNA. For the ECA109 cell line, Scratch wound-healing assays (E, F) and transwell migration healing assays (G, H) were conducted to evaluate the migration capability influenced by FABP6, accompanied by their respective statistical representations. Similarly, for the KYSE30 cell line, Scratch wound-healing assays (I, J) and transwell migration healing assays (K, L) were performed to assess migration ability regulated by FABP6, along with corresponding statistical illustrations. The scale bar for Figure 7E and 7I represent 250 μm, while Figure 7G, 7K feature a scale bar of 50 μm. Statistical analysis revealed significant differences between the groups (*p < 0.05, ***p < 0.001).